According to the existing data, the probability of HER‐2 mutations is 1.67% in breast cancer, 1–4% in lung cancer and 2.9% in colorectal 6, 7, 8, 9, 10, 11, 12. The gene discussed is ERBB2; the disease is lung carcinoma.